BioFuse Series A Equity Funding

Min. Invest
$25,000
Target Hold
48 mos.
Target IRR
25%
hand_instruments_biofuse.png

BioFuse Generator1.png

BioFuse Tissue Management System 400-N

BioFuse Instrument1.png

BioFuse instrument

BioFuse weld1.png

BioFuse Sealing

Project Summary

BioFuse Medical Technologies, Inc. is a privately held medical device technology company engaged in the research, development and commercialization of an innovative, automated surgical tissue management system. The SurgiFuse system holds an FDA 510(k) clearance for tissue sealing. The Company expects to build upon its portfolio of intellectual property and existing FDA clearances with true soft tissue welding capabilities. The technology platform has the potential to improve patient outcomes in vessel and duct sealing as well as a broad variety of surgical procedures.

Used in Europe, not yet FDA approved/cleared.  Not for sale in the USA.

Form of Security Equity Offering
Term 48 Months
Offering Size $2,000,000
Target IRR 25%

Why Invest?

  • Effective and Proven technology
  • Large and Growing markets
  • Experienced Medical Device Management team with a history of product commercialization and M&A successes
  • Clear path to profitability with high margin recurring revenue model
  • Company holds FDA 510(k) clearance for initial application of duct and vessel sealing
  • Product roadmap includes tissue welding applications for colorectal anastomosis and pulmonary resections
  • Large medical device companies and physicians are seeking safer and newer technologies as an alternative to sutures, staples and meshes - which to the body are considered 'foreign body' objects
  • Target Investors:  aggressive accredited health care/technology investors seeking equity participation in an early stage medical technology company for a minimum investment of $25,000.

Financial Summary

Current Shares Outstanding  17,440,690
Pre-Money Valuation  $15,000,000
Value Per Share  $0.86
Anticipated Equity Offering $2,000,000
Post Money Valuation $17,000,000
Number New Shares 2,325,425
Dilution 11.8%
Post Offering:
Total Shares Outstanding  19,766,115

 

Financial Sources

Series A Common Stock Offering of $2,000,000

Seed Round of $1.7mm completed in 2017 @  $0.34/share

Over $12.6mm invested through BioFuse and prior entity, Live Tissue Connect, Inc.

Financial Uses

Fund product development of BioFuse 2nd generation tissue management system.

Build the Company’s new product pipeline through additional advanced R&D and clinical studies.

Apply for regulatory approvals, US and international patents.

Hire senior management, operational and sales and marketing personnel.

Purchase of inventory, products, services and/or technologies.

General corporate purposes, including working capital, offering expenses, operating expenses & future capital expenditures.

Property Summary


Market Summary

Demand for “advanced, innovative” devices that vastly improve outcomes
Increase demand to replace or monitor staples under recall , i.e. Ethicon 2019
March 2019, FDA indicated 41,000 “adverse event reports” for staplers, 2011-18
Continued focus on MIS to reduce hospital stays & costs
Surgeons want new technologies to eliminate scars & lower infection rates

Source
Market Watch, 2019, Mordor Intelligence 2017, Researchgate.net, Future Business Insight 2018, Kake -2020
MEDTECH DIVE, Oct 31, 2019

Frequently Asked Questions

Contact Sponsor

Required fields are denoted by an asterisk (*).

Name *
Email *
Phone
Message *

Investor Tutorial

CERTAIN INFORMATION REGARDING THIS OFFERING

THESE UNITS ARE BEING OFFERED WITHOUT REGISTRATION UNDER ANY FEDERAL OR STATE SECURITIES LAWS, BUT ARE BEING OFFERED UNDER AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND UNDER COMPARABLE EXEMPTIONS UNDER VARIOUS STATE SECURITIES LAWS. HOWEVER, THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”) HAS NOT DETERMINED THAT THESE UNITS ARE EXEMPT FROM REGISTRATION. THESE UNITS HAVE NOT BEEN REVIEWED, APPROVED OR DISAPPROVED BY THE COMMISSION OR ANY STATE SECURITIES COMMISSION, NOR HAS THE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE ACCURACY, ADEQUACY, COMPLETENESS OR MERITS OF THIS MEMORANDUM, AND ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. THIS MEMORANDUM DOES NOT CONSTITUTE AN OFFER TO SELL TO, OR A SOLICITATION OF AN OFFER TO BUY FROM, NOR SHALL ANY OF THE UNITS BE OFFERED OR SOLD TO, ANY PERSON IN ANY JURISDICTION IN WHICH SUCH AN OFFER, SOLICITATION, PURCHASE, OR SALE IS UNLAWFUL OR UNAUTHORIZED UNDER THE SECURITIES LAWS OF SUCH JURISDICTION.

THE STATEMENTS MADE HEREIN ARE MADE AS OF THE DATE ON THE COVER OF THIS OFFERING MEMORANDUM. THIS OFFERING MEMORANDUM CONSTITUTES AN INVITATION TO THE PROSPECTIVE INVESTOR TO SUBMIT AN OFFER TO SUBSCRIBE. NO PERSON MAY PURCHASE THE UNITS OFFERED HEREBY EXCEPT PURSUANT TO AN EXECUTED SUBSCRIPTION AGREEMENT IN THE FORM PRESCRIBED BY THE FUND, AND THEN ONLY FROM A PERSON TO WHOM THE FUND OR ITS DESIGNATED AGENT HAS DELIVERED A COPY OF THIS OFFERING MEMORANDUM.

THESE UNITS ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED BY THE FUND. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THERE IS CURRENTLY NO PUBLIC MARKET FOR THESE UNITS.

IN MAKING A DECISION TO PURCHASE UNITS HEREUNDER, PROSPECTIVE INVESTORS MUST CONDUCT THEIR OWN INDEPENDENT INVESTIGATION OF THE FUND AND THE TERMS OF THIS OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED, AND ARE ENCOURAGED TO CONSULT WITH THEIR ADVISORS AS THEY WILL BE REQUIRED TO REPRESENT THAT THEY ARE ABLE TO BEAR THE ECONOMIC RISK OF THEIR INVESTMENT AND THAT THEY ARE FAMILLIAR WITH AND UNDERSTAND THE FUNDAMENTAL RISKS AND TERMS OF THIS OFFERING.

NO PERSON HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION OR MAKE ANY REPRESENTATION WITH RESPECT TO THE OFFERING OF THE UNITS WHICH IS NOT CONTAINED OR REFERENCED HEREIN, AND, IF GIVEN OR MADE, SUCH INFORMATION OR REPRESENTATION MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED BY THE FUND. POTENTIAL INVESTORS MAY, IF THEY SO DESIRE, MAKE INQUIRIES OF THE FUND WITH RESPECT TO THE FUND’S BUSINESS OR ANY OTHER MATTERS SET FORTH HEREIN, AND MAY OBTAIN ANY ADDITIONAL INFORMATION WHICH SUCH PERSON DEEMS TO BE NECESSARY IN ORDER TO VERIFY THE ACCURACY OF THE INFORMATION CONTAINED IN THIS MEMORANDUM (TO THE EXTENT THAT THE FUND POSSESSES SUCH INFORMATION OR CAN ACQUIRE IT WITHOUT UNREASONABLE EFFORT OR EXPENSE).

October 17 2021

Confidential Offering Memorandum: BioFuse Medical Technologies, Inc.

PROSPECTIVE INVESTORS ARE CAUTIONED NOT TO CONSTRUE ANY CONTENTS OF THIS OFFERING MEMORANDUM OR ANY PRIOR OR SUBSEQUENT COMMUNICATIONS, AS CONSTITUTING INVESTMENT, LEGAL OR TAX ADVICE; RATHER THEY SHOULD CONSULT THEIR OWN ADVISORS OR COUNSEL WITH THE CAPACITY TO ADVISE AND PROTECT THEIR INTEREST IN CONNECTION WITH ALL MATTERS CONCERNING THIS OFFERING MEMORANDUM.

THIS OFFERING MEMORANDUM DOES NOT KNOWINGLY CONTAIN ANY UNTRUE STATEMENT OF A MATERIAL FACT OR OMIT A MATERIAL FACT, AND ANY SUCH MISSTATEMENT OR OMISSION IS DONE WITHOUT THE KNOWLEDGE OF THE PREPARERS OF THIS DOCUMENT OR THE FUND. AS SUCH THE FUND BELIEVES THAT THIS OFFERING MEMORANDUM CONTAINS A FAIR SUMMARY OF THE MATERIAL TERMS OF ALL MATTERS, DOCUMENTS AND CIRCUMSTANCES MATERIAL TO THIS OFFERING. WHILE THE DATA AND STATEMENTS CONTAINED HEREIN ARE BASED UPON INFORMATION BELIEVED TO BE RELIABLE, NO WARRANTY CAN BE MADE AS TO THE ACCURACY OF SUCH INFORMATION OR THAT CIRCUMSTANCES HAVE NOT CHANGED SINCE THE DATE SUCH INFORMATION WAS SUPPLIED. THIS MEMORANDUM CONTAINS SUMMARIES OF CERTAIN PROVISIONS OF DOCUMENTS RELATING TO THE BUSINESS OF THE FUND AND THE UNITS OFFERED HEREBY, AS WELL AS SUMMARIES OF VARIOUS PROVISIONS OF RELEVANT STATUTES AND REGULATIONS. SUCH SUMMARIES DO NOT PURPORT TO BE COMPLETE AND ARE QUALIFIED IN THEIR ENTIRETY BY REFERENCE TO THE TEXTS OF THE ORIGINAL DOCUMENTS, STATUTES AND REGULATIONS.